TY - JOUR T1 - Efficacy of Paclitaxel-based Chemotherapy After Progression on Nivolumab for Head and Neck Cancer JF - In Vivo JO - In Vivo SP - 1211 LP - 1215 DO - 10.21873/invivo.12371 VL - 35 IS - 2 AU - YASUYOSHI SATO AU - NAOKI FUKUDA AU - YU FUJIWARA AU - XIAOFEI WANG AU - TETSUYA URASAKI AU - AKIHIRO OHMOTO AU - KENJI NAKANO AU - MAKIKO ONO AU - JUNICHI TOMOMATSU AU - HIROKI MITANI AU - SHUNJI TAKAHASHI Y1 - 2021/03/01 UR - http://iv.iiarjournals.org/content/35/2/1211.abstract N2 - Background/Aim: In the CheckMate-141 trial regarding head and neck cancer (HNC), nivolumab conferred a survival benefit to patients. However, the best treatment sequence of chemotherapy and anti-PD-1/PD-L1 therapy in these cancers is unclear. Patients and Methods: This was an observational study using data collected prospectively from 97 HNC patients treated with nivolumab at our institutions. Twenty-two HNC patients who received paclitaxel-based chemotherapy before (pre-PTX, n=12) and after (post-PTX, n=10) nivolumab were evaluated. Results: The median follow-up time was 15.9 months (range=6.9-35.9 months). There was a significant difference in the overall response rate (ORR) between pre-PTX (17%) and post-PTX (70%) (p=0.027). Similarly, time to progression (TTP) was significantly longer after nivolumab than before nivolumab (post-PTX, 7.4 months; pre-PTX, 4.9 months, p=0.020). Conclusion: Paclitaxel-based chemotherapy had a better ORR and TTP after nivolumab than before nivolumab for HNC. The sequential administration of anti-PD-1 therapy followed by paclitaxel-based chemotherapy could be a better strategy for HNC. ER -